Medicare ‘Maximum Fair Price’ And The Importance Of Choosing The Right Therapeutic Alternatives
Biopharma industry raises alarm that Medicare might identify therapeutic comparators for drugs selected for price negotiation based mainly on costs.
You may also be interested in...
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.
The Pink Sheet's updated guide to comment deadlines and decision dates for Medicare's new drug pricing program.
CMS should adopt the minimum price reductions under the Inflation Reduction Act for most selected drugs in the early years of the Medicare price negotiation program, PhRMA urges and recommends the agency should retain that approach in the long-term for younger drugs, those targeting an unmet medical need or those representing therapeutic advances.